Increlex market seen growing through 2026 as diagnosis and treatment expand

The Increlex market is expected to expand through 2026 as better diagnosis of growth disorders, broader pediatric endocrinology access and rising healthcare spending lift demand. North America held the largest share in 2025 and is projected to keep the lead through 2026.

Why it matters: - The Increlex market is tied to how quickly clinicians identify and treat severe growth disorders in children. - Better screening, more access to pediatric endocrinology and wider use of personalized growth treatments could expand demand for mecasermin. - The market outlook also reflects broader spending on rare-disease care and digital monitoring tools.

What happened: - The Business Research Company published an analysis of the Increlex global market through 2026, with longer-range forecasts through 2035. - The report says North America held the largest share of the Increlex market in 2025. - North America is projected to remain the leading region through 2026. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available online. - The full report is also available online.

The details: - Increlex is the brand name for mecasermin, a recombinant human insulin-like growth factor-1, or rhIGF-1. - The treatment is designed for children with growth failure caused by severe primary IGF-1 deficiency. - The report links past market growth to better diagnosis of IGF-1 deficiency, wider availability of pediatric endocrinology services, approval of recombinant growth factor therapies, stronger screening programs and greater awareness among healthcare professionals. - Expected growth drivers include personalized pediatric growth treatments, more investment in rare-disease therapies, digital tools for growth monitoring, a stronger focus on long-term outcomes and advances in recombinant protein manufacturing. - Expected trends include broader use of recombinant growth therapies, greater focus on pediatric endocrine disorders, wider implementation of precision dosing, earlier diagnosis and more comprehensive long-term growth tracking. - The report highlights childhood-onset growth hormone deficiency as a key driver. - The condition is linked to delayed growth and shorter stature because the body does not produce enough growth hormone during childhood. - In November 2023, data from the Council of Health Insurance in Saudi Arabia showed CGHD affects about 1 in 3,500 to 1 in 10,000 children, with higher frequency among boys. - Rising global healthcare spending is also supporting market expansion. - In November 2025, the OECD estimated average health expenditure per capita in member countries at nearly $6,000 in 2024, adjusted for purchasing power. - The United States was the highest spender among OECD countries.

Between the lines: - The market story is less about a single drug and more about improved detection of rare pediatric conditions that can make therapies like Increlex more relevant. - North America’s lead suggests the strongest near-term demand is likely to remain in markets with advanced specialty care and higher adoption of recombinant treatments. - The emphasis on digital monitoring and precision dosing points to a shift toward more individualized pediatric care rather than broad, one-size-fits-all treatment.

What's next: - The report expects the market to benefit from continued growth in personalized pediatric growth care and rare-disease investment. - Additional reporting tools in the 2026 edition include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated trend graphics. - The Business Research Company is offering expert contact points for follow-up inquiries and sales support.

The bottom line: - Increlex demand is positioned to rise as healthcare systems diagnose more children with severe growth disorders and expand access to specialized treatment.